

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request **Ein Cyf / Our Ref: 23-E-011**

You asked:

1. How many of the following intra-vitreous injections/implants has your Health Board administered in the four-month period from January to April 2023:

- Aflibercept - 1976
- Bevacizumab - 0
- Brolucizumab - 0
- Dexamethasone - 78
- Faricimab - 397
- Fluocinolone acetonide - 0
- Ranibizumab – Lucentis - <5*
- Ranibizumab – Ongavia - 0
- Ranibizumab – Byooviz - 0
- Ranibizumab – Ximluci - 0

2. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2023:

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept	1924	45	7
Bevacizumab	0	0	0
Brolucizumab	0	0	0
Dexamethasone	0	78	0
Faricimab	397	0	0
Ranibizumab	0	0	0



* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

